PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT3469923

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
MIDCAP FINANCIAL TRUST	07/29/2015

RECEIVING PARTY DATA

Name:	IMMUNE PHARMACEUTICALS, LTD.
Street Address:	430 EAST 29TH STREET
Internal Address:	SUITE 940
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10016

PROPERTY NUMBERS Total: 2

Property Type	Number
Application Number:	61643368
Application Number:	11902194

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: lagould@mintz.com

Correspondent Name: MINTZ LEVIN

Address Line 1: ONE FINANCIAL CENTER
Address Line 2: STEPHANIE LEOPOLD

Address Line 4: BOSTON, MASSACHUSETTS 02111

ATTORNEY DOCKET NUMBER:	46981-001
NAME OF SUBMITTER:	LESLIE GOULD
SIGNATURE:	/lesliegould/
DATE SIGNED:	08/05/2015

Total Attachments: 7

source=MidCapImmuneRelease2#page1.tif source=MidCapImmuneRelease2#page2.tif source=MidCapImmuneRelease2#page3.tif source=MidCapImmuneRelease2#page4.tif

PATENT 503423289 REEL: 036254 FRAME: 0090

source=MidCapImmuneRelease2#page5.tif
source=MidCapImmuneRelease2#page6.tif
source=MidCapImmuneRelease2#page7.tif

RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY

THIS RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (this "Release") is made as of July 29, 2015 ("Effective Date") by MIDCAP FINANCIAL TRUST, in its capacity as Administrative Agent ("Grantee"), in favor of IMMUNE PHARMACEUTICALS, LTD. (the "Grantor").

WHEREAS, pursuant to the terms and conditions of that certain Intellectual Property Security Agreement, dated as of February 19, 2014 (the "February 2014 Agreement"), Grantor assigned, transferred and conveyed to Grantee, and granted to Grantee, a security interest in all of Grantor's right, title and interest in and to the Intellectual Property Collateral (as defined in the February 2014 Agreement, the "Intellectual Property Collateral");

WHEREAS, the February 2014 Security Agreement was recorded with the United States Patent and Trademark Office on February 19, 2014 at Reel 032277, Frame 0132.

WHEREAS, Grantee has consented to the release of the lien on all of the Intellectual Property Collateral, including but not limited to the patents listed on <u>Schedule 1</u> hereto (collectively, the "<u>Released IP Collateral</u>");

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Grantee hereby covenants and agrees as follows:

- 1. Grantee's mortgage, pledge, and hypothecation and lien on and security interest in the Released IP Collateral is hereby terminated and released.
- 2. To the extent Grantee retains any such interest, Grantee hereby assigns, transfers and conveys to Grantor, all of Grantee's right, title and interest, now owned or hereinafter acquired, that it may have whether by assignment or otherwise, in and to any mortgage and continuing security interest and collateral assignment in the Released IP Collateral. Such assignment, transfer and conveyance by Grantee is made without any representation or warranty (express or implied) by Grantee.
- 3. Grantee hereby agrees to execute, acknowledge and deliver all such further instruments and to take all such further actions as may be reasonably requested or are required in order to more fully and effectively carry out the purposes of this Release, all at the expense of Grantor. Grantee authorizes Grantor (or its agents) to file such documentation as is necessary to effect the releases of the Intellectual Property Collateral granted hereunder.
- 4. This Release may be executed in counterparts, each of which will be deemed an original, but all of which together constitute one and the same original. Delivery of an executed counterpart of a signature page to this Release by facsimile or other electronic transmission shall be effective as delivery of a manually executed counterpart of this Release.

[the remainder of this page intentionally left blank]

IN WITNESS WHEREOF, Grantee has caused this Release to be executed by its duly authorized representative as of the Effective Date.

MIDCAP FINANCIAL TRUST

By: Apollo Capital Management, L.P.,

its investment manager

By: Apollo Capital Management GP, LLC,

its general partner

By: ______ (SEAL)

Name: Maurice Amsellem Title: Authorized Signatory

Schedule 1

[See attached]

Schedule 1 to Release of Security Interest in Intellectual Property

EXHIBIT A

Copyrights

DescriptionRegistration/
ApplicationRegistration/
ApplicationNumberDate

50641593_2

EXHIBIT B

Patents

<u>Description</u>	Registration/ Application <u>Number</u>	Registration/ Application <u>Date</u>
METHOD OF GENERATING HUMAN MONOCLONAL ANTIBODIES	61/643,368	May 7, 2012
NUCLEOTIDE AND PROTEIN SEQUENCES OF ANTIBODY DIRECTED AGAINST AN EPITOPE COMMON TO HUMAN ACIDIC AND BASIC FERRITINS, MONOCLONAL ANTIBODIES OR ANTIBODY- LIKE MOLECULES COMPRISING THESE SEQUENCES AND USE THEREOF	11/902,194	September 19, 2007

EXHIBIT C

Trademarks

DescriptionRegistration/
ApplicationRegistration/
ApplicationNumberDate

50641593_2

EXHIBIT D

Mask Works

Registration/ Application Number Registration/ Application <u>Date</u> **Description**

50641593_2